Study outcomes
injection-site, infections
ASYMPTOMATIC SARS-COV-2 INFECTION, SECONDARY, INFECTIONS
The primary objective was to evaluate humoral immune responses of candidate SARS-CoV-2 variant vaccines, alone or in combination. The secondary objective was to evaluate the safety of candidate SARS-CoV-2 variant vaccines assessed by solicited injection-site and systemic AEs, which were collected for 7 days after vaccination; unsolicited AEs through day 29; and serious AEs, new-onset chronic medical conditions, AEs of special interest, AEs leading to withdrawal and medically attended AEs through the duration of the trial.Exploratory objectives included sequencing strains from infections for variant spike lineage and assessing anti-N serology. Information on antigen- or PCR-confirmed symptomatic or asymptomatic SARS-CoV-2 infection at any time after randomization was collected.